Therapy Areas: Inflammatory Diseases
NeuroSense Therapeutics granted US patent protection for use of PrimeC combination in Alzheimer's disease
22 January 2026 - NeuroSense Therapeutics Ltd (NASDAQ:NRSN), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, announced on Wednesday that ...
LEO Pharma advances delgocitinib cream into phase 3 trial for lichen sclerosus
21 January 2026 - Danish pharmaceutical company LEO Pharma A/S said on Wednesday that it has initiated the phase 3 DELTA CARE 1 trial to evaluate the efficacy and safety of Anzupgo (delgocitinib) crea...
HistoIndex partners Houston Research Institute
21 January 2026 - HistoIndex, a Singapore-based developer of AI-driven digital pathology solutions for chronic liver disease, said on Tuesday that it has formed a strategic partnership with Houston Re...
Formosa Pharmaceuticals licenses APP13007 ophthalmic therapy to Samil for South Korea
12 January 2026 - Taiwanese biotechnology company Formosa Pharmaceuticals, Inc. (TWSE: 6838) announced on Monday that it has entered an exclusive licensing agreement with South Korea-based pharmaceuti...
Eli Lilly agrees to acquire Ventyx Biosciences
8 January 2026 - Pharmaceutical company Eli Lilly and Company (NYSE:LLY) announced on Wednesday that it has signed a definitive agreement to acquire Ventyx Biosciences Inc (Nasdaq:VTYX), a clinical-st...
Bambusa Therapeutics reports first patient dosed in proof-of-concept COPD trial
7 January 2026 - Clinical-stage biotechnology company Bambusa Therapeutics Inc announced on Tuesday that the first patient has been dosed in the Phase Ib clinical trial of BBT002, a novel platform-in-...